

## **Anglian Water (Osprey) Financing Plc**

(incorporated with limited liability in England and Wales under the United Kingdom Companies Act 2006, as amended from time to time, with registered number 7476767)

### £10,000,000,000

# Global Secured Medium Term Note Programme unconditionally and irrevocably guaranteed by, inter alios,

### **Osprey Acquisitions Limited**

(incorporated with limited liability in England and Wales with registered number 5915896)

This Supplement (the "Supplement") to the prospectus dated 10 October 2023 (the "Base Prospectus"), as supplemented on 13 December 2023 (the "Prospectus") constitutes a supplement to the prospectus for the purposes of Article 23 of the UK Prospectus Regulation and is prepared in connection with the £10,000,000,000 Global Secured Medium Term Note Programme (the "Programme") established by Anglian Water (Osprey) Financing plc (the "Issuer"). When used in this Supplement, "UK Prospectus Regulation" means Regulation (EU) 2017/1129 as it forms part of domestic law.

This Supplement is supplemental to, and should be read in conjunction with, the Prospectus and any other supplements to the Prospectus issued by the Issuer. The purpose of this Supplement is to incorporate by reference the supplement to the AWS Base Prospectus (the "AWS Supplemental Prospectus").

Unless otherwise defined in this Supplement, terms defined in the Prospectus have the same meaning when used in this Supplement. Unless stated otherwise, page numbers referred to in this Supplement refer to pages in the Prospectus.

The Issuer, Osprey Acquisitions Limited ("OAL") and Osprey Investco Limited ("OIL") (together, being the "Obligors") accepts responsibility for the information contained in this Supplement. To the best of the knowledge of each of the Issuer and the other Obligors, the information contained in this Supplement is in accordance with the facts and this Supplement makes no omission likely to affect its import.

#### **Documents Incorporated by Reference**

The AWS Supplemental Prospectus dated as at the date of this Supplement shall, by virtue of this Supplement, be incorporated in, and form part of, the Prospectus.

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Prospectus by this Supplement and (b) any other statement in or incorporated by reference in the Prospectus, the statements in (a) above will prevail.

Save as disclosed in this Supplement, there has been no other significant new factor, material mistake or material inaccuracy relating to information included in the Prospectus since the publication of the Prospectus.

If documents which are incorporated by reference into this Supplement themselves incorporate any information or other documents therein, either expressly or implicitly, such information or other documents will not form part of this Supplement for the purposes of the UK Prospectus Regulation except where such information or other documents are specifically incorporated by reference or where this Supplement is specifically defined as including such information.

This Supplement has been approved by the FCA, which is the United Kingdom competent authority for the purposes of Article 23 of the UK Prospectus Regulation in the United Kingdom, as a base prospectus supplement issued in compliance with the UK Prospectus Regulation. The FCA only approves this Supplement as meeting the standards of completeness,

comprehensibility and consistency imposed by the UK Prospectus Regulation, and such approval should not be considered as an endorsement of the Issuer.